Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
This study has been terminated.
Study NCT00061620   Information provided by M.D. Anderson Cancer Center
First Received: May 30, 2003   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Malignancies
Additional conditions recognized in this trial
Hematologic Neoplasms
Neoplasms
More general conditions related to this trial
Hematologic Diseases
Neoplasms by Site
Interventions listed in this trial
Tezacitabine (FMdC)
Additional drug interventions recognized in this trial
2'-deoxy-2'-(fluoromethylene)cytidine
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Chiron Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services